Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
BeiGene Australia Pty Ltd
Scientific Title
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors